Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Tyro3 is a podocyte protective factor in glomerular disease
Fang Zhong, … , Zhihong Liu, John Cijiang He
Fang Zhong, … , Zhihong Liu, John Cijiang He
Published November 15, 2018
Citation Information: JCI Insight. 2018;3(22):e123482. https://doi.org/10.1172/jci.insight.123482.
View: Text | PDF
Research Article Nephrology

Tyro3 is a podocyte protective factor in glomerular disease

  • Text
  • PDF
Abstract

Our previous work demonstrated a protective role of protein S in early diabetic kidney disease (DKD). Protein S exerts antiinflammatory and antiapoptotic effects through the activation of TYRO3, AXL, and MER (TAM) receptors. Among the 3 TAM receptors, we showed that the biological effects of protein S were mediated largely by TYRO3 in diabetic kidneys. Our data now show that TYRO3 mRNA expression is highly enriched in human glomeruli and that TYRO3 protein is expressed in podocytes. Interestingly, glomerular TYRO3 mRNA expression increased in mild DKD but was suppressed in progressive DKD, as well as in focal segmental glomerulosclerosis (FSGS). Functionally, morpholino-mediated knockdown of tyro3 altered glomerular filtration barrier development in zebrafish larvae, and genetic ablation of Tyro3 in murine models of DKD and Adriamycin-induced nephropathy (ADRN) worsened albuminuria and glomerular injury. Conversely, the induction of TYRO3 overexpression specifically in podocytes significantly attenuated albuminuria and kidney injury in mice with DKD, ADRN, and HIV-associated nephropathy (HIVAN). Mechanistically, TYRO3 expression was suppressed by activation of TNF-α/NF-κB pathway, which may contribute to decreased TYRO3 expression in progressive DKD and FSGS, and TYRO3 signaling conferred antiapoptotic effects through the activation of AKT in podocytes. In conclusion, TYRO3 plays a critical role in maintaining normal podocyte function and may be a potential new drug target to treat glomerular diseases.

Authors

Fang Zhong, Zhaohong Chen, Liwen Zhang, Yifan Xie, Viji Nair, Wenjun Ju, Matthias Kretzler, Robert G. Nelson, Zhengzhe Li, Hongyu Chen, Yongjun Wang, Aihua Zhang, Kyung Lee, Zhihong Liu, John Cijiang He

×

Figure 5

Global knockout of Tyro3 increases albuminuria and glomerulosclerosis in ADRN mice.

Options: View larger image (or click on image) Download as PowerPoint
Global knockout of Tyro3 increases albuminuria and glomerulosclerosis in...
(A) Urinary albumin/creatinine ratio (μg/μg) in control WT, control Tyro3 KO (KO), ADR-injected WT (WT-ADR), and ADR-injected Tyro3 KO (KO-ADR). (B) Twelve-hour albumin excretion (μg) in control and ADRN mice. (C) Periodic acid-Schiff–stained kidney images at 200× and 400× magnifications. Scale bar: 50 μm (D) Semiquantification of glomerulosclerosis in control and ADRN mice. For all datasets, n = 6 in each group; data are shown as mean ± SEM; statistical analysis was performed with 2-way (A) or 1-way ANOVA (B and D); *P < 0.05, ***P < 0.001, and ****P < 0.0001 when compared with vehicle-injected control mice; #P < 0.05, ##P < 0.01, and ####P < 0.0001 when compared with WT-ADR mice.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts